DZ3399A1 - Composition de vaccin polyvalent - Google Patents

Composition de vaccin polyvalent

Info

Publication number: DZ3399A1
Authority: DZ; Algeria
Prior art keywords: vaccine composition; versatile; versatile vaccine; composition; vaccine
Prior art date: 2000-06-29

Application number

DZ013399A

Other languages

English (en)

Inventor

Dominique Boutriau

Carine Capiau

Pierre Michel Desmons

Dominique Lemoine

Jan Poolman

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-29

Filing date

2001-06-27

Publication date

2002-01-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27255788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ3399(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-29 Priority claimed from GBGB0015999.6A external-priority patent/GB0015999D0/en

2001-04-03 Priority claimed from GBGB0108364.1A external-priority patent/GB0108364D0/en

2001-04-03 Priority claimed from GB0108363A external-priority patent/GB0108363D0/en

2001-06-27 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

2002-01-03 Application granted granted Critical

2002-01-03 Publication of DZ3399A1 publication Critical patent/DZ3399A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

DZ013399A 2000-06-29 2001-06-27 Composition de vaccin polyvalent DZ3399A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB0015999.6A GB0015999D0 (en)	2000-06-29	2000-06-29	Novel compounds
GBGB0108364.1A GB0108364D0 (en)	2001-04-03	2001-04-03	Vaccine composition
GB0108363A GB0108363D0 (en)	2001-04-03	2001-04-03	Vaccine composition
PCT/EP2001/007288 WO2002000249A2 (fr)	2000-06-29	2001-06-27	Composition vaccinale

Publications (1)

Publication Number	Publication Date
DZ3399A1 true DZ3399A1 (fr)	2002-01-03

Family

ID=27255788

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ013399A DZ3399A1 (fr)	2000-06-29	2001-06-27	Composition de vaccin polyvalent

Country Status (34)

Country	Link
US (2)	US20030180316A1 (fr)
EP (4)	EP2277541A1 (fr)
JP (2)	JP4870895B2 (fr)
KR (3)	KR100898845B1 (fr)
CN (2)	CN1449293B (fr)
AP (1)	AP1695A (fr)
AT (1)	ATE534402T1 (fr)
AU (2)	AU8189501A (fr)
BG (2)	BG66238B1 (fr)
BR (2)	BR122012003821B8 (fr)
CA (2)	CA2412497C (fr)
CY (2)	CY1112280T1 (fr)
CZ (1)	CZ20024224A3 (fr)
DK (2)	DK1296715T4 (fr)
DZ (1)	DZ3399A1 (fr)
EA (2)	EA006313B1 (fr)
EG (1)	EG24742A (fr)
ES (2)	ES2375704T5 (fr)
HU (3)	HU228384B1 (fr)
IL (2)	IL153506A0 (fr)
MA (1)	MA25824A1 (fr)
MX (1)	MXPA03000198A (fr)
MY (1)	MY133981A (fr)
NO (1)	NO332495B1 (fr)
NZ (1)	NZ523319A (fr)
OA (1)	OA12302A (fr)
PE (1)	PE20020126A1 (fr)
PL (2)	PL393584A1 (fr)
PT (2)	PT1946769E (fr)
SI (2)	SI1946769T1 (fr)
SK (1)	SK288007B6 (fr)
UA (2)	UA85853C2 (fr)
UY (1)	UY26801A1 (fr)
WO (1)	WO2002000249A2 (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4540795B2 (ja) *	2000-03-10	2010-09-08	一般財団法人阪大微生物病研究会	生ワクチンの細胞性免疫活性を不活化ワクチンにも起こさせる方法、及びこれより得られる混合ワクチン
GB0108364D0 (en) *	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
ES2375704T5 (es)	2000-06-29	2016-03-03	Smithkline Beecham Biologicals S.A.	Composición de vacuna multivalente
HRP20030598B1 (hr)	2001-01-23	2013-05-31	Aventis Pasteur	Multivalentna meningokokalna polisaharidno-proteinska konjugirana vakcina
AU2007200116A1 (en) *	2001-04-03	2007-02-01	Glaxosmithkline Biologicals S.A.	Vaccine composition
CA2448066A1 (fr)	2001-05-31	2002-12-12	Chiron Corporation	Particules de replicon d'alphavirus chimerique
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
DE60328481D1 (de)	2002-05-14	2009-09-03	Novartis Vaccines & Diagnostic	Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) *	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
BR0310042A (pt) *	2002-05-14	2005-04-05	Chiron Srl	Vacinas de combinação mucosal para meningite bacteriana
DK1549338T3 (da)	2002-10-11	2011-03-28	Novartis Vaccines & Diagnostic	Polypeptidvacciner til bred beskyttelse mod hypervirulente meningokok-afstamningslinier
KR101130948B1 (ko) *	2002-11-01	2012-03-30	글락소스미스클라인 바이오로지칼즈 에스.에이.	건조 공정
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
JP2006516609A (ja) *	2003-01-30	2006-07-06	カイロンソチエタアレスポンサビリタリミタータ	粘膜髄膜炎菌性ワクチン
WO2004067030A2 (fr) *	2003-01-30	2004-08-12	Chiron Srl	Vaccins injectables contre les multiples serogroupes du meningocoque
CN1819843A (zh)	2003-05-07	2006-08-16	安万特巴斯德公司	增强脑膜炎球菌疫苗接种免疫原性的方法
GB0313916D0 (en)	2003-06-16	2003-07-23	Glaxosmithkline Biolog Sa	Vaccine composition
BRPI0411875A (pt) *	2003-06-23	2006-08-08	Sanofi Pasteur Inc	método de imunização contra os sorogrupos a e c de neisseria meningitidis
BRPI0415025A (pt)	2003-10-02	2006-12-12	Chiron Srl	vacinas lìquidas para sorogrupos meningocócicos múltiplos
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
CU23404A1 (es) *	2003-11-19	2009-08-04	Ct Ingenieria Genetica Biotech	Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
GB0405787D0 (en) *	2004-03-15	2004-04-21	Chiron Srl	Low dose vaccines
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
PT1740217E (pt)	2004-04-30	2011-08-02	Novartis Ag	Vacinação meningocócica conjugada
GB0409745D0 (en) *	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0502096D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Purification of streptococcal capsular polysaccharide
GB0505518D0 (en) *	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) *	2005-04-08	2011-06-07	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en)	2005-04-08	2007-08-09	Wyeth	Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2006235013B2 (en)	2005-04-08	2011-11-03	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) *	2005-04-08	2010-05-04	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1871411A4 (fr)	2005-04-18	2010-07-21	Novartis Vaccines & Diagnostic	Procede pour exprimer un antigene de surface de virus de l'hepatite b afin de preparer un vaccin
PE20070163A1 (es)	2005-06-27	2007-03-01	Glaxosmithkline Biolog Sa	Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
GB0513069D0 (en) *	2005-06-27	2005-08-03	Glaxosmithkline Biolog Sa	Immunogenic composition
CN1709505B (zh) *	2005-07-13	2010-06-16	北京绿竹生物制药有限公司	多价细菌荚膜多糖-蛋白质结合物联合疫苗
CN102973929B (zh)	2005-09-01	2017-04-26	诺华疫苗和诊断有限两合公司	含血清群c脑膜炎球菌的多价疫苗
JP2009511636A (ja)	2005-10-18	2009-03-19	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
GB0522765D0 (en)	2005-11-08	2005-12-14	Chiron Srl	Combination vaccine manufacture
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
GB0607088D0 (en) *	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
EP3020411A1 (fr) *	2005-12-22	2016-05-18	GlaxoSmithKline Biologicals s.a.	Vaccin
WO2007071786A2 (fr) *	2005-12-23	2007-06-28	Glaxosmithkline Biologicals Sa	Vaccin
CN101374859B (zh) *	2006-01-17	2014-11-26	阿恩·福斯格伦	新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)
PL2004225T3 (pl)	2006-03-22	2012-09-28	Novartis Ag	Schematy immunizacji koniugatami meningokokowymi
TW200806315A (en) *	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en)	2006-05-08	2014-08-19	Wyeth Llc	Pneumococcal dosing regimen
EP1872791A1 (fr)	2006-06-30	2008-01-02	Institut Pasteur	Utilisation de polysaccharides bactériens pour empêcher la formation d'un film biologique
AU2007293672B2 (en)	2006-09-07	2013-06-27	Glaxosmithkline Biologicals S.A.	Vaccine
JP2010525035A (ja)	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
US20100203137A1 (en)	2007-06-04	2010-08-12	Mario Contorni	Formulation of meningitis vaccines
MX2009013949A (es)	2007-06-26	2010-05-24	Glaxosmithkline Biolog Sa	Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
KR20110053314A (ko) *	2008-05-30	2011-05-20	더 유에스에이, 애즈 리프리젠티드 바이 더 세크리터리 오브 더 아미, 온 비하프 오브 월터 리드 아미	수막구균성 다가 천연 외막 소포체 백신, 이의 제조 방법 및 사용 방법
PE20100365A1 (es) *	2008-10-24	2010-05-21	Panacea Biotec Ltd	Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
TW201136603A (en) *	2010-02-09	2011-11-01	Merck Sharp & Amp Dohme Corp	15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
SI2575870T1 (sl) *	2010-06-04	2017-01-31	Wyeth Llc	Formulacije cepiva
HRP20160362T1 (hr)	2010-12-14	2016-05-06	Glaxosmithkline Biologicals S.A.	Antigeni pripravak protiv bakterija iz roda mycobacterium
BR112013017171B1 (pt)	2011-01-05	2019-12-17	Bharat Biotech International Limited	composição combinada heptavalente estável
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
DE102011122891B4 (de)	2011-11-11	2014-12-24	Novartis Ag	Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de)	2011-11-11	2014-02-13	Novartis Ag	Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
EP2592137A1 (fr)	2011-11-11	2013-05-15	Novartis AG	Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
GB2495341B (en)	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products
US9198977B2 (en) *	2012-01-30	2015-12-01	Serum Institute Of India Ltd.	Immunogenic composition
EP2822584A1 (fr) *	2012-03-08	2015-01-14	Novartis AG	Vaccins combinés comprenant des agonistes du tlr4
AU2013301312A1 (en)	2012-08-06	2015-03-19	Glaxosmithkline Biologicals S.A.	Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
KR20150065878A (ko)	2012-10-12	2015-06-15	글락소스미스클라인 바이오로지칼즈 에스.에이.	조합 백신에서 사용하기 위한 가교되지 않은 무세포 백일해 항원
KR20150072444A (ko) *	2012-10-17	2015-06-29	글락소스미스클라인 바이오로지칼즈 에스.에이.	하나 이상의 스트렙토코커스 뉴모니애 캡슐 사카라이드 컨쥬게이트 및 해모필루스 인플루엔자로부터의 단백질 Ｅ 및／또는 ＰｉｌＡ를 포함하는 단백질 성분을 포함하는 면역원성 조성물
KR20140075201A (ko) *	2012-12-11	2014-06-19	에스케이케미칼주식회사	다가 폐렴구균 다당류-단백질 접합체 조성물
KR102236498B1 (ko)	2013-03-08	2021-04-06	얀센 백신스 앤드 프리벤션 비.브이.	무세포 백일해 백신
EP3019513B1 (fr) *	2013-07-07	2018-01-17	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Vaccins synthétiques contre le streptococcus pneumoniae type 1
CN105555304A (zh)	2013-08-05	2016-05-04	葛兰素史密丝克莱恩生物有限公司	联合免疫原性组合物
US11160855B2 (en) *	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9107906B1 (en)	2014-10-28	2015-08-18	Adma Biologics, Inc.	Compositions and methods for the treatment of immunodeficiency
RU2626532C2 (ru) *	2015-01-16	2017-07-28	Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации	Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
US10888611B2 (en) *	2015-02-19	2021-01-12	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
EP3493840B1 (fr)	2016-08-05	2022-08-24	Sanofi Pasteur Inc.	Composition d'un conjugué polysaccharide-protéine pneumococcique multivalent
CN109862908B (zh)	2016-08-05	2023-05-02	圣诺菲·帕斯图尔公司	多价肺炎球菌多糖-蛋白质缀合物组合物
KR102692762B1 (ko)	2016-09-02	2024-08-08	사노피 파스퇴르 인크	네이세리아 메닌기티디스 백신
US10259865B2 (en)	2017-03-15	2019-04-16	Adma Biologics, Inc.	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN117982633A (zh)	2017-12-06	2024-05-07	默沙东有限责任公司	包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
IL276229B2 (en)	2018-02-05	2024-01-01	Sanofi Pasteur Inc	Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3089007A1 (fr)	2018-02-05	2019-08-08	Sanofi Pasteur Inc.	Composition de conjugues polysaccharide-proteine pneumococcique multivalents
EP3782642A4 (fr)	2018-04-18	2022-04-13	SK Bioscience Co., Ltd.	Polysaccharides capsulaires de streptococcus pneumoniae et conjugués immunogènes de ceux-ci
US11896656B2 (en) *	2018-04-30	2024-02-13	Merck Sharp & Dohme Llc	Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
KR20200005458A (ko)	2018-07-06	2020-01-15	주식회사 유바이오로직스	다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물
WO2020095324A1 (fr) *	2018-11-10	2020-05-14	Bharat Biotech International Limited	Compositions immunogènes de glycoconjugués multivalents
CR20210333A (es)	2018-12-19	2021-08-18	Merck Sharp & Dohme	Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
CA3141460A1 (fr)	2019-05-20	2020-11-26	Soligenix, Inc.	Compositions et procedes de fabrication de vaccins anti-filovirus trivalents
CN111821432B (zh) *	2020-08-05	2022-10-18	北京智飞绿竹生物制药有限公司	一种多价肺炎球菌结合疫苗
WO2025109417A1 (fr) *	2023-11-21	2025-05-30	Panacea Biotec Limited	Composition immunogène d'haemophilus influenzae conjuguée à la protéine d

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4057685A (en) *	1972-02-02	1977-11-08	Abbott Laboratories	Chemically modified endotoxin immunizing agent
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (fr) *	1979-09-21	1986-04-16	Hitachi, Ltd.	Interrupteur à semiconducteur
US4372945A (en)	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en)	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4673574A (en) *	1981-08-31	1987-06-16	Anderson Porter W	Immunogenic conjugates
US4459286A (en) *	1983-01-31	1984-07-10	Merck & Co., Inc.	Coupled H. influenzae type B vaccine
JPS6061288A (ja) *	1983-09-13	1985-04-09	Fuji Photo Film Co Ltd	感熱記録材料
US4808700A (en) *	1984-07-09	1989-02-28	Praxis Biologics, Inc.	Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en)	1985-06-07	1987-11-24	President And Fellows Of Harvard College	Modified toxic vaccines
GB8516442D0 (en)	1985-06-28	1985-07-31	Wellcome Found	Cloned antigen
GB8727489D0 (en)	1987-11-24	1987-12-23	Connaught Lab	Detoxification of pertussis toxin
GB8914122D0 (en)	1989-06-20	1989-08-09	Wellcome Found	Polypeptide expression
SE466259B (sv)	1990-05-31	1992-01-20	Arne Forsgren	Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2059692C (fr) *	1991-01-28	2004-11-16	Peter J. Kniskern	Vaccin conjugue de polysaccharide contre les pneumocoques
WO1993021769A1 (fr)	1992-05-06	1993-11-11	President And Fellows Of Harvard College	Region de liaison du recepteur de la toxine de la diphterie
ATE444079T1 (de)	1992-05-23	2009-10-15	Glaxosmithkline Biolog Sa	Kombinierte impfstoffe, die hepatitis b oberfläche antigen und andere antigenen enthalten
JP3428646B2 (ja)	1992-06-18	2003-07-22	プレジデントアンドフェローズオブハーバードカレッジ	ジフテリア毒素ワクチン
UA40597C2 (uk)	1992-06-25	2001-08-15	Смітклайн Бічем Байолоджікалс С.А.	Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
DE69323264D1 (de) *	1992-10-27	1999-03-11	American Cyanamid Co	Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
KR100376361B1 (ko) *	1993-09-22	2003-07-18	헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신	면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
US5849301A (en) *	1993-09-22	1998-12-15	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5869058A (en) *	1994-05-25	1999-02-09	Yeda Research And Development Co. Ltd.	Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6455673B1 (en)	1994-06-08	2002-09-24	President And Fellows Of Harvard College	Multi-mutant diphtheria toxin vaccines
US5917017A (en)	1994-06-08	1999-06-29	President And Fellows Of Harvard College	Diphtheria toxin vaccines bearing a mutated R domain
DK0772619T4 (da)	1994-07-15	2011-02-21	Univ Iowa Res Found	Immunmodulatoriske oligonukleotider
GB9422096D0 (en) *	1994-11-02	1994-12-21	Biocine Spa	Combined meningitis vaccine
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69612198T3 (de) *	1995-06-23	2011-08-18	Smithkline Beecham Biologicals S.A.	Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat
US5997881A (en)	1995-11-22	1999-12-07	University Of Maryland, Baltimore	Method of making non-pyrogenic lipopolysaccharide or A
EP0973911A1 (fr)	1997-01-30	2000-01-26	Imperial College Of Science, Technology & Medicine	GENES MUTANTS $i(msbB) ou $i(htrB)
AU4707097A (en) *	1997-09-15	1999-04-05	Pasteur Merieux Serums Et Vaccins	Multivalent vaccines
US5965714A (en) *	1997-10-02	1999-10-12	Connaught Laboratories, Inc.	Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en)	1998-02-23	2006-03-28	Aventis Pasteur, Inc	Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9806456D0 (en) *	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition
US6146902A (en) *	1998-12-29	2000-11-14	Aventis Pasteur, Inc.	Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB9925559D0 (en)	1999-10-28	1999-12-29	Smithkline Beecham Biolog	Novel method
FR2806304B1 (fr) *	2000-03-17	2002-05-10	Aventis Pasteur	Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0108364D0 (en) *	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
ES2375704T5 (es)	2000-06-29	2016-03-03	Smithkline Beecham Biologicals S.A.	Composición de vacuna multivalente
US20040096461A1 (en) *	2002-07-30	2004-05-20	Baxter Healthcare Corporation	Chimeric multivalent polysaccharide conjugate vaccines
GB0405787D0 (en) *	2004-03-15	2004-04-21	Chiron Srl	Low dose vaccines
GB0500787D0 (en) *	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0428394D0 (en) *	2004-12-24	2005-02-02	Chiron Srl	Saccharide conjugate vaccines
GB0502095D0 (en) *	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
PE20070163A1 (es) *	2005-06-27	2007-03-01	Glaxosmithkline Biolog Sa	Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
GB0607088D0 (en) *	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
EP3020411A1 (fr) *	2005-12-22	2016-05-18	GlaxoSmithKline Biologicals s.a.	Vaccin
WO2007071786A2 (fr) *	2005-12-23	2007-06-28	Glaxosmithkline Biologicals Sa	Vaccin
GB0700135D0 (en) *	2007-01-04	2007-02-14	Glaxosmithkline Biolog Sa	Vaccine
GB0700136D0 (en) *	2007-01-04	2007-02-14	Glaxosmithkline Biolog Sa	Process for manufacturing vaccines
US8885224B2 (en) *	2007-03-14	2014-11-11	Konica Minolta Business Technologies, Inc.	Information embedding method, its program and information embedding device
JP2010525035A (ja) *	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
US20100203137A1 (en) *	2007-06-04	2010-08-12	Mario Contorni	Formulation of meningitis vaccines
MX2009013949A (es) *	2007-06-26	2010-05-24	Glaxosmithkline Biolog Sa	Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.

2001
- 2001-06-27 ES ES01960390.1T patent/ES2375704T5/es not_active Expired - Lifetime
- 2001-06-27 DK DK01960390.1T patent/DK1296715T4/en active
- 2001-06-27 KR KR1020087013186A patent/KR100898845B1/ko not_active Expired - Lifetime
- 2001-06-27 OA OA1200200395A patent/OA12302A/en unknown
- 2001-06-27 BR BR122012003821A patent/BR122012003821B8/pt not_active IP Right Cessation
- 2001-06-27 HU HU0301413A patent/HU228384B1/hu unknown
- 2001-06-27 MY MYPI20013027 patent/MY133981A/en unknown
- 2001-06-27 KR KR1020077019832A patent/KR20070091698A/ko not_active Ceased
- 2001-06-27 PT PT07116669T patent/PT1946769E/pt unknown
- 2001-06-27 JP JP2002505030A patent/JP4870895B2/ja not_active Expired - Lifetime
- 2001-06-27 CA CA2412497A patent/CA2412497C/fr not_active Expired - Lifetime
- 2001-06-27 US US10/312,090 patent/US20030180316A1/en not_active Abandoned
- 2001-06-27 EP EP10178451A patent/EP2277541A1/fr not_active Withdrawn
- 2001-06-27 HU HU1000594A patent/HU227613B1/hu unknown
- 2001-06-27 MX MXPA03000198A patent/MXPA03000198A/es active IP Right Grant
- 2001-06-27 HU HU1000593A patent/HU227893B1/hu unknown
- 2001-06-27 EP EP07116669A patent/EP1946769B1/fr not_active Expired - Lifetime
- 2001-06-27 ES ES07116669T patent/ES2385100T3/es not_active Expired - Lifetime
- 2001-06-27 PL PL393584A patent/PL393584A1/pl unknown
- 2001-06-27 WO PCT/EP2001/007288 patent/WO2002000249A2/fr not_active Ceased
- 2001-06-27 EA EA200201240A patent/EA006313B1/ru not_active IP Right Cessation
- 2001-06-27 BR BRPI0112057A patent/BRPI0112057B8/pt not_active IP Right Cessation
- 2001-06-27 IL IL15350601A patent/IL153506A0/xx unknown
- 2001-06-27 CN CN018146198A patent/CN1449293B/zh not_active Expired - Lifetime
- 2001-06-27 PL PL360265A patent/PL210015B1/pl unknown
- 2001-06-27 EG EG20010701A patent/EG24742A/xx active
- 2001-06-27 SK SK1843-2002A patent/SK288007B6/sk not_active IP Right Cessation
- 2001-06-27 PT PT01960390T patent/PT1296715E/pt unknown
- 2001-06-27 DZ DZ013399A patent/DZ3399A1/fr active
- 2001-06-27 UA UAA200604994A patent/UA85853C2/uk unknown
- 2001-06-27 AP APAP/P/2002/002700A patent/AP1695A/en active
- 2001-06-27 NZ NZ523319A patent/NZ523319A/en not_active IP Right Cessation
- 2001-06-27 PE PE2001000629A patent/PE20020126A1/es not_active Application Discontinuation
- 2001-06-27 KR KR1020027017928A patent/KR100837917B1/ko not_active Expired - Lifetime
- 2001-06-27 SI SI200131012T patent/SI1946769T1/sl unknown
- 2001-06-27 UA UA20021210397A patent/UA76952C2/uk unknown
- 2001-06-27 DK DK07116669.8T patent/DK1946769T3/da active
- 2001-06-27 EP EP01960390.1A patent/EP1296715B2/fr not_active Expired - Lifetime
- 2001-06-27 SI SI200131007T patent/SI1296715T2/sl unknown
- 2001-06-27 AU AU8189501A patent/AU8189501A/xx active Pending
- 2001-06-27 AU AU2001281895A patent/AU2001281895C1/en not_active Expired
- 2001-06-27 CN CN200910174266.7A patent/CN101708333B/zh not_active Expired - Lifetime
- 2001-06-27 EA EA200501070A patent/EA011480B1/ru not_active IP Right Cessation
- 2001-06-27 CA CA2783274A patent/CA2783274C/fr not_active Expired - Lifetime
- 2001-06-27 CZ CZ20024224A patent/CZ20024224A3/cs not_active IP Right Cessation
- 2001-06-27 UY UY26801A patent/UY26801A1/es not_active IP Right Cessation
- 2001-06-27 EP EP10178449A patent/EP2279748A1/fr not_active Withdrawn
- 2001-06-27 AT AT01960390T patent/ATE534402T1/de active
2002
- 2002-12-17 IL IL153506A patent/IL153506A/en active IP Right Grant
- 2002-12-20 NO NO20026175A patent/NO332495B1/no not_active IP Right Cessation
- 2002-12-26 MA MA26980A patent/MA25824A1/fr unknown
- 2002-12-28 BG BG107422A patent/BG66238B1/bg unknown
2009
- 2009-11-06 BG BG10110518A patent/BG66249B1/bg unknown
2010
- 2010-03-15 JP JP2010057779A patent/JP5346308B2/ja not_active Expired - Lifetime
2012
- 2012-01-30 CY CY20121100103T patent/CY1112280T1/el unknown
- 2012-04-04 US US13/439,829 patent/US9233151B2/en not_active Expired - Fee Related
- 2012-06-15 CY CY20121100549T patent/CY1112915T1/el unknown

Also Published As

Publication number	Publication date
HU1000593D0 (en)	2010-12-28
DK1296715T3 (da)	2012-02-13
CN101708333A (zh)	2010-05-19
BG107422A (bg)	2003-09-30
CY1112280T1 (el)	2015-12-09
EP1946769A3 (fr)	2008-07-30
JP5346308B2 (ja)	2013-11-20
SK288007B6 (sk)	2012-10-02
JP4870895B2 (ja)	2012-02-08
WO2002000249A3 (fr)	2002-06-13
CN101708333B (zh)	2014-03-26
US20120207780A1 (en)	2012-08-16
EA200201240A1 (ru)	2003-06-26
PL360265A1 (en)	2004-09-06
UY26801A1 (es)	2002-01-31
BR122012003821B1 (pt)	2020-09-01
ES2375704T5 (es)	2016-03-03
EA200501070A1 (ru)	2006-02-24
HU1000594D0 (en)	2010-12-28
BRPI0112057B1 (pt)	2016-10-04
CA2412497A1 (fr)	2002-01-03
PT1296715E (pt)	2012-01-19
KR100837917B1 (ko)	2008-06-13
EP1296715B2 (fr)	2015-12-23
NO20026175D0 (no)	2002-12-20
SI1296715T1 (sl)	2012-03-30
EP2279748A1 (fr)	2011-02-02
DK1296715T4 (en)	2016-03-07
HU227613B1 (en)	2011-09-28
WO2002000249A2 (fr)	2002-01-03
CN1449293B (zh)	2012-08-22
JP2004501873A (ja)	2004-01-22
BG66249B1 (en)	2012-09-28
KR20030024714A (ko)	2003-03-26
NO20026175L (no)	2003-02-26
HUP0301413A1 (hu)	2003-08-28
HU228384B1 (en)	2013-03-28
ES2375704T3 (es)	2012-03-05
KR20070091698A (ko)	2007-09-11
US9233151B2 (en)	2016-01-12
PL393584A1 (pl)	2011-05-23
HU227893B1 (en)	2012-05-29
UA85853C2 (uk)	2009-03-10
US20030180316A1 (en)	2003-09-25
EP1296715B1 (fr)	2011-11-23
EP1946769A2 (fr)	2008-07-23
ES2385100T3 (es)	2012-07-18
JP2010163453A (ja)	2010-07-29
CA2412497C (fr)	2012-10-02
ATE534402T1 (de)	2011-12-15
UA76952C2 (uk)	2006-10-16
AU2001281895B2 (en)	2005-04-28
MXPA03000198A (es)	2004-09-13
PL210015B1 (pl)	2011-11-30
EP1296715A2 (fr)	2003-04-02
AP2002002700A0 (en)	2002-12-31
CN1449293A (zh)	2003-10-15
MA25824A1 (fr)	2003-07-01
CA2783274A1 (fr)	2002-01-03
IL153506A0 (en)	2003-07-06
AU2001281895C1 (en)	2005-10-27
KR20080052700A (ko)	2008-06-11
BG110518A (bg)	2010-04-30
CZ20024224A3 (cs)	2003-05-14
MY133981A (en)	2007-11-30
EA006313B1 (ru)	2005-10-27
IL153506A (en)	2009-06-15
PT1946769E (pt)	2012-06-27
BR122012003821B8 (pt)	2021-05-25
EP2277541A1 (fr)	2011-01-26
HUP0301413A3 (en)	2010-01-28
DK1946769T3 (da)	2012-07-16
NZ523319A (en)	2006-01-27
SI1296715T2 (sl)	2016-03-31
OA12302A (en)	2003-10-24
AU8189501A (en)	2002-01-08
BR0112057A (pt)	2003-06-17
BG66238B1 (bg)	2012-08-31
NO332495B1 (no)	2012-10-01
EG24742A (en)	2010-07-14
EA011480B1 (ru)	2009-04-28
BRPI0112057B8 (pt)	2021-05-25
EP1946769B1 (fr)	2012-05-30
CY1112915T1 (el)	2016-04-13
CA2783274C (fr)	2018-08-07
KR100898845B1 (ko)	2009-05-21
PE20020126A1 (es)	2002-04-27
SI1946769T1 (sl)	2012-07-31
SK18432002A3 (sk)	2003-08-05
AP1695A (en)	2006-12-17
HK1055244A1 (en)	2004-01-02

Publication	Publication Date	Title
DZ3399A1 (fr)	2002-01-03	Composition de vaccin polyvalent
FR13C0072I1 (fr)	2014-01-31	Nouvelle composition de vaccin
ATE553775T1 (de)	2012-05-15	Impstoffzusammesetzung
NO20031483D0 (no)	2003-04-01	Vaksine
NO20024172D0 (no)	2002-09-02	Vaksine
PL363005A1 (pl)	2004-11-15	Szczepionki
DE60045324D1 (de)	2011-01-13	Impfstoffzusammensetzung
AR028204A1 (es)	2003-04-30	Composiciones farmaceuticas electrohiladas
FI20105657L (fi)	2010-06-10	Farmaseuttisia koostumuksia
DK1524266T3 (da)	2007-06-25	Farmaceutisk sammensætning
ATE321569T1 (de)	2006-04-15	Kombinierte impfstoffzusammensetzungen
EP1572124A4 (fr)	2007-11-28	Compositions de vaccin vhc e1e2
ITMI20010748A0 (it)	2001-04-06	Composizioni farmaceutiche
ITTO20010008A0 (it)	2001-01-10	Formulazione farmaceutica
EP1423141A4 (fr)	2005-08-03	Vaccin
EP1461077A4 (fr)	2006-01-25	Immunogene polyvalent
DK1427444T3 (da)	2013-11-04	West-nil-vaccine
DZ3219A1 (fr)	2001-02-22	Vaccin
NO20033882D0 (no)	2003-09-02	Vaksine
NO20026123L (no)	2003-02-18	Farmasöytiske sammensetninger
EP1565583A4 (fr)	2007-11-21	Formulations de vaccin anti-vih
NO20031095L (no)	2003-03-10	Farmasoytiske sammensetninger
EP1420818A4 (fr)	2008-07-02	Compositions antigeniques
EE200200689A (et)	2004-06-15	Ravimkoostised